{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.09","upperLimit":"94.55","value":"81.0"},{"groupId":"OG001","lowerLimit":"28.22","upperLimit":"71.78","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Measurable CNS lesions at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.37","upperLimit":"71.49","value":"59.4"},{"groupId":"OG001","lowerLimit":"15.26","upperLimit":"39.04","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Measurable and non-measurable CNS lesions"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"CNS ORR was defined as the percentage of participants who attained CR or PR and had measurable/non-measurable CNS lesions at baseline. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure (number of participants with measurable/non-measurable CNS lesions at baseline).","reportingStatus":"POSTED","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","title":"Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}